Press Releases Items Per Page 102550 Year None2021202020192018201720162015201420132012201120102007 11.15.21 Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update 11.08.21 Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021 11.04.21 Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting 09.27.21 Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases 09.15.21 Syndax Appoints Martin H. Huber, M.D., to its Board of Directors 09.02.21 Syndax Announces Participation at Three Upcoming Investor Conferences 08.09.21 Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update 08.02.21 Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021 06.28.21 SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias 06.03.21 Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference 05.13.21 Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit 05.11.21 Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
11.15.21 Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update
11.08.21 Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021
11.04.21 Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting
09.27.21 Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
08.09.21 Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update
08.02.21 Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021
06.28.21 SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
05.11.21 Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update
